Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ucenprubart by Eli Lilly and Co for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Ucenprubart is under clinical development by Eli Lilly and Co and currently in Phase II for Atopic Dermatitis (Atopic Eczema)....
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Ucenprubart?
Ucenprubart is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Atopic Dermatitis...